Hypersensitivity pneumonitis due to venlafaxine

Archivos de Bronconeumologia

Volumn 44, Issue 10, 2008, Pages 571-573

  Clau, Luis Borderías ^a   Gómez, Miguel Ángel Marigil ^a   Adán, Pascual Val ^a   Letosa, Mariano Marcén ^a   López, Rosa Biescas ^a   López, Francisco Garrapiz ^a  

^a HOSPITAL SAN JORGE   (Spain)

Author keywords

Adverse effects; Drugs; Hypersensitivity pneumonitis; Venlafaxine

Indexed keywords

DOBUPAL; LORMETAZEPAM; MIRTAZAPINE; OLANZAPINE; UNCLASSIFIED DRUG; VENLAFAXINE; ZYPRESA; CYCLOHEXANOL DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ALLERGIC PNEUMONITIS; ARTICLE; ASTHENIA; BLOOD EXAMINATION; BLOOD GAS ANALYSIS; CASE REPORT; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DEPRESSION; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FIBEROPTIC BRONCHOSCOPY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG AUSCULTATION; LUNG BIOPSY; LUNG FUNCTION; LUNG LAVAGE; PARANOIA; PHYSICAL EXAMINATION; RADIODIAGNOSIS; THORAX RADIOGRAPHY; CHEMICALLY INDUCED DISORDER; MIDDLE AGED;

ALVEOLITIS, EXTRINSIC ALLERGIC; CYCLOHEXANOLS; FEMALE; HUMANS; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS;

EID: 55049128294     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1157/13126838     Document Type: Article

References (20)

1. Holliday SM, Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs. 1995;49:280-94.
2. Thase ME. Selective serotonin-norepinephrine reuptake inhibitors. In: Sadock BJ, Sadock VA, editors. Kaplan and Sadock's comprehensive textbook of psychiatry. 8th ed. Baltimore: Lipincott, Williams & Wilkins; 2004. p. 2881-4.
3. Melien O, Skaali T, Myhr K, Brórs O. Venlafaxine and asthma. Nord J Psychiatry. 2005;59:538-40.
4. Fleisch MC, Blauer F, Gubler JHG, Kuhn M, Scherer TA. Eosinophilic pneumonia and respiratory failure associated with venlafaxine treatment. Eur Respir J. 2000;15:205-8.
5. Oermann CM, Panesar KS, Langstom C, Larsen GL, Menéndez AA, Schofield DE, et al. Pulmonary infiltrates with eosinophilia syndromes in children. J Pediatr. 2000;136:351-8.
6. Drent M, Singh S, Gorgels APM, Hansell DM, Bekers O, Nicholson AG, et al. Drug induced pneumonitis and heart failure simultaneously associated with venlafaxine. Am J Respir Crit Care Med. 2003;167:958-61.
7. Turner RC, Nelson JE, Roberts BT, Gillam DM. Venlafaxine associated interstitial pneumonitis. Pharmacotherapy. 2005;25:626-9.
8. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med. 2003;139:683-93.
9. Camus P, Foucher P, Bonniaud P, Ask K. Drug-induced infiltrative lung disease. Eur Respir J. 2001;18 Suppl 32:93-100.
10. Carrión F, Marín J. Toxicidad pulmonar por fármacos. Arch Bronconeumol. 1999;35:550-9.
11. Hubbard R, Venn A, Smith C, Cooper M, Johnston I, Britton J. Exposure to common prescribed drugs and the etiology of cryptogenetic fibrosing alveolitis. Am J Respir Crit Care Med. 1998;157:743-7.
12. Bass SP, Coletbbatch HJH. Fluoxetine induced lung damage. Med J Austr. 1992;156:364-5.
13. Haro M, Rubio M, Puig J. Enfermedad pulmonar asociada a la administración de fluoxetina. Arch Bronconeumol. 2002;38:153.
14. Kervelier E, Trédaniel J, Revlon G, Groussard O, Zalcman G, Ortoli JM, et al. Fluoxetin-induced pulmonary granulomatosis. Eur Respir J. 1996;9:615-7.
15. Lessard E, Yessine MA, Hamelin BA, O'Hara G, LeBlanc J, Turgeon J. Influence of CYP 2D6 activity on the deposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics. 1999;9:435-43.
16. Shams ME, Arneth B, Hiemke C, Dragicevic A, Müller MJ, Kaiser R, et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther. 2006;31:493-502.
17. Posadas SJ, Pichler WJ. Delayed drug hypersensitivity reactions - new concepts. Clin Exp Allergy. 2007;37:989-99.
18. Capelozzi MA, Leick-Maldonado EA, Parra ER, Martins MA, Tiberio IF, Capelozzi VL. Morphological and functional determinants of fluoxetine (Prozac)-induced pulmonary disease in an experimental model. Respir Physiol Neurobiol. 2007;156:171-8.
19. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45.
20. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329:15-9.